Review shows lecanemab and donanemab slow decline and explains who should get them

Retrieved on: 2025-09-25 01:48:39

Tags for this article:

Click the tags to see associated articles and topics

Review shows lecanemab and donanemab slow decline and explains who should get them. View article details on hiswai:

Excerpt

The Lancet review synthesises evidence on anti beta amyloid monoclonal antibodies and the wider Alzheimer's care pathway, weighing efficacy, ...

Article found on: www.news-medical.net